Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Genkyotex       FR0011790542

GENKYOTEX

  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (EUR)
Sales 2019 75,0 M
EBIT 2019 63,5 M
Net income 2019 52,0 M
Debt 2019 4,00 M
Yield 2019 -
Sales 2020 -
EBIT 2020 -30,2 M
Net income 2020 -23,0 M
Debt 2020 21,0 M
Yield 2020 -
P/E ratio 2019 0,69
P/E ratio 2020
EV / Sales2019 0,53x
EV / Sales2020 0
Capitalization 36,1 M
More Financials
Company
GenKyoTex SA, formerly known as Genticel SA, is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease... 
More about the company
Surperformance© ratings of Genkyotex
Trading Rating : - Investor Rating :
More Ratings
Latest news on GENKYOTEX
06:45aGENKYOTEX : Preclinical study of GKT831 shows rapid regression of cholestatic fi..
AQ
05/21GENKYOTEX : Publication of GKT831 data in the Journal of Hepatology
PU
05/21GENKYOTEX : Preclinical study of GKT831 shows rapid regression of cholestatic fi..
GL
05/04GENKYOTEX : Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Tr..
AQ
05/02Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Li..
GL
05/01GENKYOTEX : Conference Call
AQ
05/01GENKYOTEX : Conference Call at 2pm Paris time on 2nd MayGenkyotex Conference Cal..
PU
05/01GENKYOTEX : Conference Call at 2pm Paris time on 2nd May
PU
04/25Genkyotex Provides Corporate Update and Reports Cash Position at March 31, 20..
GL
04/15GENKYOTEX : Reverse Stock Split Takes Effect
GL
More news
Analyst Recommendations on GENKYOTEX
More recommendations
Sector news : Bio Therapeutic Drugs
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Bio Therapeutic Drugs
Chart GENKYOTEX
Duration : Period :
Genkyotex Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 21,7 €
Spread / Average Target 381%
EPS Revisions
Managers
NameTitle
Elias Papatheodorou Chief Executive Officer & Director
Claudio Nessi Chairman
Alexandre Grassin Vice President-Finance & Administration
Philippe Wiesel Chief Medical Officer & Executive Vice President
Jesús Martin-Garcia Director
Sector and Competitors
1st jan.Capitalization (M$)
GENKYOTEX-13.39%40
GILEAD SCIENCES6.35%83 745
VERTEX PHARMACEUTICALS2.06%42 447
REGENERON PHARMACEUTICALS-17.01%32 595
GENMAB12.27%10 632
SAREPTA THERAPEUTICS INC11.05%8 718